-Advertisement-
-Advertisement-
Home
Positive trial results announced for TTHX1114 in patients with fuchs endothelial corneal dystrophy
Cornea and External Disease
Positive trial results announced for TTHX1114 in patients with fuchs endothelial corneal dystrophy
Trefoil Therapeutics recently announced positive Phase 2 results for TTHX1114, an engineered fibroblast growth factor-1 (FGF1) variant, in patients with fuchs endothelial corneal dystrophy (FECD). TTHX1114 is delivered as an intracameral injection into the anterior chamber of the eye of patients undergoing a Descemet Stripping Only (DSO) procedure. After a...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Contact Info
© 2024 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved